at Zacks.com (Dec 31, 2014)
Zogenix (ZGNX +6.7%) moves up after announcing its preliminary Q4 sales figures today. The...
Zogenix (ZGNX +6.7%) moves up after announcing its preliminary Q4 sales figures today. The company expects gross product sales of approximately $13.5M on 145,200 units shipped, with unit volume up approximately 9% sequentially from Q312 and 26% from Q411. For FY12, preliminary unaudited net product revenues were around $36M, up 18% over FY11, but slightly below previously issued guidance of $37M. Separately the drug developer adds that it's filed for a $75M mixed shelf registration.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Benzinga.com (Dec 29, 2014)
at CNBC.com (Apr 10, 2014)
at CNBC.com (Mar 14, 2014)
at CNBC.com (Mar 5, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs